Fonar (FONR) Stock Price, News & Analysis

Company Overview

Fonar Corporation is a medical technology company primarily engaged in the design, manufacture and sale of magnetic resonance imaging (MRI) systems. The company’s flagship product, the UPRIGHT® Multi-Position™ MRI, enables patients to be scanned in standing, seated and traditional recumbent positions, offering enhanced diagnostic capabilities for musculoskeletal, neurological and vascular conditions. In addition to MRI equipment sales, Fonar provides equipment installation, training and maintenance services to hospitals, imaging centers and private practices.

Headquartered in Melville, New York, Fonar markets its MRI systems both domestically and internationally, supported by a network of service engineers and customer support personnel. The company holds numerous patents covering MRI technology innovations, including its patented hydrostatic piston design that facilitates open‐gantry scanning. Fonar’s research and development efforts focus on expanding the clinical applications of multi-positional MRI, with an emphasis on improving patient comfort and diagnostic accuracy.

Through its subsidiaries, Fonar operates a chain of diagnostic imaging centers offering outpatient MRI services in key U.S. markets. These centers serve a broad spectrum of patients—from orthopedic and sports medicine referrals to neurology and spine care—leveraging Fonar’s unique imaging capabilities to inform treatment plans. The diagnostic services business complements the company’s equipment sales by providing ongoing revenue from scan fees, facility operations and patient referrals.

Founded in 1978 by Dr. Raymond V. Damadian—widely recognized as the inventor of the first MRI scanner—Fonar has maintained a pioneering role in medical imaging for over four decades. The company’s executive leadership continues to advance its core mission of developing innovative MRI solutions, expanding clinical applications and supporting healthcare providers worldwide in the early detection and management of disease.

Key Stats

• Today's Range: $18.86 to $18.88
• 50-Day Range: $18.34 to $18.94
• 52-Week Range: $13.33 to $18.95
• Volume: 9,480 shs
• Average Volume: 64,334 shs
• Market Capitalization: $116.45 million
• P/E Ratio: 18.87
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Fonar Stock Analysis - MarketRank™

Fonar scored higher than 24% of companies evaluated by MarketBeat, and ranked 766th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Fonar has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Fonar has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fonar is 18.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fonar is 18.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.61.

Price to Book Value per Share Ratio

Fonar has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.39% of the float of Fonar has been sold short.

Short Interest Ratio / Days to Cover

Fonar has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fonar has recently increased by 90.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fonar does not currently pay a dividend.

Dividend Growth

Fonar does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for FONR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fonar insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.93% of the stock of Fonar is held by insiders.

Percentage Held by Institutions

50.64% of the stock of Fonar is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/19/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:FONR
• CIK: 355019
• Web: www.fonar.com
• Phone: (631) 694-2929
• Fax: 631-753-5150
• Employees: 480
• Year Founded: 1978

Profitability

• EPS (Trailing Twelve Months): $1.00
• Trailing P/E Ratio: 18.87
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8.33 million
• Net Margins: 6.35%
• Pretax Margin: 10.80%
• Return on Equity: 4.12%
• Return on Assets: 3.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.18
• Quick Ratio: 9.00

Sales & Book Value

• Annual Sales: $105.34 million
• Price / Sales: 1.11
• Cash Flow: $2.10 per share
• Price / Cash Flow: 8.98
• Book Value: $25.81 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 6,173,000
• Free Float: 5,683,000
• Market Cap: $116.45 million
• Optionable: Not Optionable
• Beta: 0.96